Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone

•Diabetic kidney disease (DKD) develops in nearly 40% of patients with diabetes, and is a leading cause of end-stage renal disease (ESRD)•Renin-angiotensin-aldosterone system (RAAS) inhibition still remains the cornerstone of treatment of DKD with albuminuria•Finerenone has significantly reduced DKD...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of diabetes and its complications 2024-05, Vol.38 (5), p.108741-108741, Article 108741
Hauptverfasser:	Filardi, Tiziana, Feraco, Alessandra, Ouvrard-Pascaud, Antoine, Rizzo, Manfredi, Caprio, Massimiliano
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardio-renal-metabolic risk Chronic kidney disease Diabetes Diabetic kidney disease Finerenone Genotype & phenotype Glucose Hyperkalemia Kidney diseases Metabolism Mineralocorticoid receptor Mortality Patients Type 2 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!